title: Comparative proteomics study on meglumine antimoniate sensitive and resistant Leishmania tropica isolated from Iranian anthroponotic cutaneous leishmaniasis patients.
abstract: In order to define the protein expressional changes related to the process of meglumine antimoniate resistance in anthroponotic cutaneous leishmaniasis (CL), we performed a comparative proteomics analysis on sensitive and resistant strains of Leishmania tropica isolated from Iranian CL patients. Cell proteins were analysed with 2-dimensional electrophoresis and differentially expressed proteins were identified by matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Image analysis of the matched maps identified 7 proteins that were either over- or down-expressed: activated protein kinase c receptor(LACK), alpha tubulin (x2), prostaglandin f2-alpha synthase, protein disulfide isomerase, vesicular transport protein and a hypothetical protein. The study shows the usefulness of proteomics in identifying proteins that may express differences between sensitive and resistant L. tropica isolates.
authors.affiliation: Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. hajaranh@tums.ac.ir
authors.forename: H
authors.initials: H
authors.lastname: Hajjaran
authors.forename: B
authors.initials: B
authors.lastname: Azarian
authors.forename: M
authors.initials: M
authors.lastname: Mohebali
authors.forename: R
authors.initials: R
authors.lastname: Hadighi
authors.forename: A
authors.initials: A
authors.lastname: Assareh
authors.forename: B
authors.initials: B
authors.lastname: Vaziri
mesh_terms: D000981:Antiprotozoal Agents; D002478:Cells, Cultured; D004352:Drug Resistance, Microbial; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D007492:Iran; D007895:Leishmania tropica / Q000187:drug effects* / Q000302:isolation & purification; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology; D008536:Meglumine / Q000494:pharmacology* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D040901:Proteomics
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate